Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT) (NCT03674047)

🧪 Interventions in This Study

• ruxolitinib (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (7 Sites)

• City of Hope Cancer Center — Duarte, California
• H. Lee Moffitt Cancer Center — Tampa, Florida
• Massachusetts General Hospital — Boston, Massachusetts
• Cleveland Clinic — Cleveland, Ohio
• Huntsman Cancer Institute — Salt Lake City, Utah
• Fred Hutchinson Cancer Center — Seattle, Washington
• Medical College of Wisconsin — Milwaukee, Wisconsin

📞 Contact the Study Coordinator

Phone: (800) 826-4673

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Other Cancer

• Development of an Intervention to Enhance Cancer Pain Management — Boston, Massachusetts

Explore by condition: All Other Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.